Literature DB >> 9538022

Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.

P J Larson1, R M Camire, D Wong, N C Fasano, D M Monroe, P B Tracy, K A High.   

Abstract

This report describes the expression, purification, and characterization of a series of recombinant factor Xa variants bearing aspartate substitutions for each of the glutamate residues which normally undergo gamma-carboxylation. Factor X was expressed in human embryonic kidney cells and purified from conditioned media by immunoaffinity and hydroxylapatite chromatography. Factor X was activated with Russell's viper venom factor X activator, and single-chain unactivated factor X was removed from activated factor X by size-exclusion chromatography. Recombinant wild-type factor Xa had normal activity in a clotting assay, and mutants with aspartate substitutions for glas residues 16, 26, and 29 had no detectable clotting activity. In purified component assays, these gla variants had essentially no detectable activity in the prothrombinase complex assembled on synthetic phospholipid vesicles but had significant activity when the prothrombinase was assembled on thrombin-activated platelets. In addition, the gla 32 variant had normal activity in the platelet prothrombinase but diminished activity in prothrombinase assembled on synthetic PSPC vesicles. These differences were not accounted for by the total phospholipid composition of the thrombin-activated platelet membrane. We have produced fully active recombinant human factor Xa and demonstrated that gla residues 16, 26, and 29 are critical for normal activity of factor Xa. More importantly, this study provides an extensive characterization of macromolecular enzyme complex formation with gla variants of a vitamin K-dependent coagulation protein and provides evidence that prothrombinase complex assembly on thrombin-activated platelets is not equivalent to assembly on synthetic phospholipid vesicles. The data suggest that thrombin-activated platelets possess some element(s) (other than 30% phosphatidyl serine or factor Va), presumably either protein or phospholipid, that serves as a component of the factor Xa binding site.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9538022     DOI: 10.1021/bi972428p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.

Authors:  Giulia Pavani; Lacramioara Ivanciu; Armida Faella; Oscar A Marcos-Contreras; Paris Margaritis
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

2.  A rapid pro-hemostatic approach to overcome direct oral anticoagulants.

Authors:  Nabil K Thalji; Lacramioara Ivanciu; Robert Davidson; Phyllis A Gimotty; Sriram Krishnaswamy; Rodney M Camire
Journal:  Nat Med       Date:  2016-07-25       Impact factor: 53.440

3.  Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity.

Authors:  Jeremy P Wood; Jay R Silveira; Nicole M Maille; Laura M Haynes; Paula B Tracy
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

Review 4.  Vitamin K-Dependent Protein Activation: Normal Gamma-Glutamyl Carboxylation and Disruption in Disease.

Authors:  Kathleen L Berkner; Kurt W Runge
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

5.  The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly.

Authors:  Raffaella Toso; Hua Zhu; Rodney M Camire
Journal:  J Biol Chem       Date:  2008-05-06       Impact factor: 5.157

6.  Computational study of coagulation factor VIIa's affinity for phospholipid membranes.

Authors:  Olivier Taboureau; Ole Hvilsted Olsen
Journal:  Eur Biophys J       Date:  2006-11-28       Impact factor: 2.095

7.  A candidate activation pathway for coagulation factor VII.

Authors:  Tina M Misenheimer; Kraig T Kumfer; Barbara E Bates; Emily R Nettesheim; Bradford S Schwartz
Journal:  Biochem J       Date:  2019-10-15       Impact factor: 3.857

8.  Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.

Authors:  Daniël Verhoef; Koen M Visscher; C Ruben Vosmeer; Ka Lei Cheung; Pieter H Reitsma; Daan P Geerke; Mettine H A Bos
Journal:  Nat Commun       Date:  2017-09-13       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.